Biomarkers of Thrombosis in ST-Segment Elevation Myocardial Infarction: A Substudy of the ATOLL Trial Comparing Enoxaparin Versus Unfractionated Heparin

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
Johanne SilvainATOLL Investigators

Abstract

The aim was to compare the peri-procedural biomarkers of coagulation and platelet activation in patients randomly allocated to intravenous enoxaparin or unfractionated heparin (UFH) in the ATOLL randomized trial (NCT00718471). A total of 129 patients (n = 58 enoxaparin and n = 71 UFH) admitted for ST-segment elevation myocardial infarction (STEMI) treated by percutaneous coronary intervention (PCI) were included in this substudy of the ATOLL trial. Activated partial thromboplastin time ratio, anti-Xa activity, von Willebrand factor antigen, prothrombin fragment 1 + 2 (F1 + 2), thrombin-antithrombin complex (TAT), tissue factor pathway inhibitor and soluble CD40 ligand were measured at sheath insertion (T1) and at the end of the PCI (T2) and correlated with 1-month clinical outcomes. Target anticoagulation levels at T2 were more readily achieved in patients receiving enoxaparin compared to those receiving UFH (80.3 vs 18.2%, p < 0.0001). Increased levels of F1 + 2 and TAT measured at T2 were associated with the incidence of the composite ischemic endpoint (p = 0.04 and p = 0.03) and all-cause mortality (p < 0.0001 and p = 0.002). Release of F1 + 2 between T1 and T2 also predicted the composite ischemic endpoint (312 ± 513 vs 37 ...Continue Reading

References

May 20, 1999·Journal of the American College of Cardiology·Y H LiJ H Chen
Jul 18, 2000·Journal of the American College of Cardiology·G MontalescotD Thomas
Jul 5, 2003·Blood·Diego ArdissinoPier Mannuccio Mannucci
May 19, 2005·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Maria BorentainPhilippe Lechat
Sep 8, 2006·The New England Journal of Medicine·Gilles MontalescotUNKNOWN STEEPLE Investigators
May 24, 2008·The New England Journal of Medicine·Gregg W StoneUNKNOWN HORIZONS-AMI Trial Investigators
Feb 23, 2010·Journal of the American College of Cardiology·Johanne SilvainGilles Montalescot
Sep 10, 2013·The American Journal of Cardiology·Jean-Philippe ColletUNKNOWN ATOLL Investigators
Nov 1, 2013·The New England Journal of Medicine·Philippe Gabriel StegUNKNOWN EUROMAX Investigators

❮ Previous
Next ❯

Citations

Jun 13, 2020·Platelets·Veronika ZapilkoPierre Fontana
Jul 18, 2020·Circulation. Cardiovascular Interventions·Guillaume DuthoitGilles Montalescot
Sep 17, 2020·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Giuseppe Musumeci, Gianmarco Annibali
Apr 14, 2020·Current Pharmaceutical Design·Konstantinos MourouzisDimitris Tousoulis
Apr 14, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Min QiuJunzhi Lin

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

© 2022 Meta ULC. All rights reserved